Kambô for Health & Longevity

Evidence Review created on 10/08/2026 using AI4L / Opus 5.5

Also known as: Kambo, Kampô, Kampo, Sapo, Kapum, Vacina do Sapo, Toad Vaccine, Frog Vaccine, Phyllomedusa bicolor Secretion, Giant Leaf Frog Secretion, Giant Monkey Frog Secretion

Motivation

Kambô is the waxy skin secretion of the giant monkey frog (Phyllomedusa bicolor), a tree frog of the Amazon rainforest. In a Kambô session, a practitioner burns a few small dots into the skin and applies the secretion to the fresh wounds, setting off a short, intense reaction dominated by vomiting. The secretion is rich in small protein fragments that act on the gut, the blood vessels and the body’s own pain-relief system, so it draws interest as a natural “cleanse” with drug-like strength.

Indigenous peoples of the western Amazon have long used Kambô to strengthen hunters and drive out bad luck. Over the past two decades it has spread to wellness retreats in Europe, North America and Australia, where people seek it for mood, recovery from addiction and relief of pain. This spread has drawn attention from chemists, psychiatrists, emergency physicians and health regulators.

This review examines what the human evidence shows about Kambô’s effects on well-being, substance use and pain, what harms have been documented, which people face the greatest danger, and how sessions are typically structured, from the perspective of health-focused adults weighing it within a long-term health plan.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

This section lists overview reviews, expert commentary and regulatory commentary that discuss Kambô in depth.

• The Amazonian kambô frog Phyllomedusa bicolor (Amphibia: Phyllomedusidae): Current knowledge on biology, phylogeography, toxinology, ethnopharmacology and medical aspects - Nogueira et al., 2022

  A transdisciplinary narrative review covering the frog’s biology, the chemistry of its secretion, the ritual’s indigenous origins and urban spread, and documented medical complications; the broadest single overview available.

• KAMBÔ: an Amazonian enigma - Haddad Junior & Martins, 2020

  A concise review by a Brazilian dermatologist and a zoologist linking each major peptide (short protein chain) in the secretion to its bodily effects, and contrasting traditional indigenous use with unsupervised urban use.

• Kambo and its Multitude of Biological Effects: Adverse Events or Pharmacological Effects? - Hesselink, 2018

  A physician-pharmacologist sympathetic to the practice argues that the acute reaction is expected peptide pharmacology rather than allergy, and proposes contraindications, water limits and conditions for safer use.

• Kambô: as DIY frog toxin kits are sold in the UK, what is the evidence and what are the risks? - Lang, 2026

  A 2026 BMJ feature on home-use Kambô kits sold in the United Kingdom, weighing the evidence for claimed benefits against reported harms.

• Kambô – leave it with frogs - Medsafe

  New Zealand’s medicines regulator summarizes the ritual, the absence of clinical evidence for benefit, and reported harms, including a national report of hypersensitivity vasculitis (allergic inflammation of small blood vessels).

None of the prioritized experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published content on Kambô; both web searches and on-site searches returned no relevant results, likely because Kambô lies outside the supplement and drug interventions these sources usually cover.

Grokipedia

Kambo (drug)

An AI-generated encyclopedia entry covering traditional use, peptide pharmacology, documented deaths, legal status by country, and conservation and cultural-appropriation debates; a broad map whose claims need checking against primary sources.

Examine

No Examine article on Kambô exists.

ConsumerLab

No ConsumerLab article on Kambô exists.

Systematic Reviews

This section lists the systematic reviews and meta-analyses of Kambô found on PubMed.

• Kambo Administration and Its Association With Sudden Death: Clinical and Forensic Perspectives From a Systematic Review - Sacco et al., 2025

  Systematic review of nine case articles on fatal and nonfatal poisoning, highlighting sudden cardiac death and esophageal rupture (a tear in the food pipe).

No systematic review or meta-analysis of any claimed benefit of Kambô exists, so the benefit side of the trade-off is unrepresented in this section.

Mechanism of Action

Kambô is a mixture of peptides that pass through the burned skin into the bloodstream within minutes; Erspamer et al. 1993 found active peptides made up to 7% of the dried secretion’s weight and matched each to symptoms:

• Phyllocaerulein: activates CCK (cholecystokinin, a gut hormone) receptors, driving nausea, vomiting and gut contractions.
• Phyllomedusin and phyllokinin: act on neurokinin and bradykinin receptors (receptors for inflammatory messengers that widen blood vessels), causing flushing, facial swelling and low blood pressure.
• Sauvagine: activates CRF (corticotropin-releasing factor, the master stress hormone) receptors, triggering a stress-hormone surge.
• Dermorphins and deltorphins: highly selective activators of μ- and δ-opioid receptors (the body’s pain-relief receptors) (Negri et al. 1992; Richter et al. 1990).
• Dermaseptins and adenoregulin: antimicrobial peptides; adenoregulin also alters binding at adenosine receptors (adenosine is a calming brain messenger) (Daly et al. 1992).

No pharmacokinetic studies (studies of how the body absorbs, distributes and clears a substance) exist in humans, so half-life (time for blood levels to halve), tissue distribution and metabolism are unknown. Peptides are presumably broken down by tissue enzymes, not the liver’s CYP (cytochrome P450) drug-processing enzymes; deltorphin A remained detectable in one fatal case’s blood (Aquila et al. 2018). Explanations compete: practitioners describe “detoxification”; a sympathetic pharmacologist attributes the reaction to expected peptide pharmacology, not allergy (Hesselink 2018); survey researchers suggest expectancy and ritual setting shape lasting effects (Majić et al. 2021).

Historical Context & Evolution

The first written account came from French missionary Constantin Tastevin in 1925, describing Amazonian groups applying frog “milk” to fresh burns to expel a “bad principle” and restore hunting luck (Hesselink 2018). Panoan-speaking hunters, including the Matsés, used it to sharpen senses and resist hunger on hunts (Daly et al. 1992; Erspamer et al. 1993).

From the 1960s to the 1990s, Vittorio Erspamer’s group in Rome and John Daly’s group at the US National Institutes of Health identified its opioid, vascular and gut-active peptides (Erspamer et al. 1993). In 1985 one peptide, dermorphin, relieved postoperative pain in a trial but never became a medicine (Hesselink & Schatman 2018).

Rubber tappers in Acre, Brazil, adopted the ritual, and in the 2000s it spread into churches using ayahuasca (a psychedelic Amazonian brew), urban clinics and Western healing circles abroad (Nogueira et al. 2022). Health-optimization interest grew through claims of detoxification, immune strengthening and relief of depression and addiction (Majić et al. 2021).

Brazil’s health agency suspended therapeutic advertising in 2004 (Nogueira et al. 2022), and Australia banned supply and use in 2021 after deaths were investigated (Sacco et al. 2025). Proponents counter that the acute reaction is expected pharmacology and that careful dosing, water limits and screening reduce serious harm (Hesselink 2018). Evidence has moved from ethnography (field study of cultures) and peptide chemistry toward harm case reports and user surveys; no controlled trial has tested the ritual.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: there are no controlled human trials of Kambô, and the only human outcome data for the ritual are uncontrolled, retrospective user surveys.

Medium 🟩 🟩

No benefit reaches Medium: no human study of Kambô includes a comparison group, so even consistent survey reports remain uncontrolled self-report.

Low 🟩

Self-reported well-being and meaning

Two retrospective surveys by one Berlin group, of 386 users (Majić et al. 2021) and 22 users (Schmidt et al. 2020), reported mostly positive persisting effects on mood and meaning. Both were self-selected and uncontrolled, so expectancy, setting and recall bias (distorted memory) cannot be separated from drug effects.

Magnitude: 87.31% of 386 respondents reported increased well-being or life satisfaction, while 3.63% regretted using Kambô (Majić et al. 2021); no control group.

Reduced alcohol and recreational drug use

In the same Berlin survey, half of respondents reported using recreational substances less often after Kambô, and most of those who sought it for addiction reported reduced use. No study verified use objectively or included a comparison group, and pre-session abstinence diets may contribute.

Magnitude: Of 75 respondents citing addiction as a motive, 28.00% reported never using the substance again and 64.00% reported using it less often (Majić et al. 2021); no control group.

Pain relief from the opioid peptide dermorphin

Dermorphin, one of the secretion’s opioid peptides, outlasted morphine for pain relief when injected into spinal fluid in 150 surgical patients in a randomized, double-blind trial (neither patients nor staff knew the drug) (Basso et al. 1985). This is indirect: a purified, injected peptide, not Kambô on burns.

Magnitude: Mean pain relief lasted 43.41 hours with spinal dermorphin versus 34.45 hours with spinal morphine (8.96 hours longer) and 10.79 hours with pentazocine (an opioid painkiller) injected into muscle; the difference was reported as significant (Basso et al. 1985).

Speculative 🟨

Greater stamina and sharper senses

Matsés hunters describe heightened senses, greater strength and resistance to hunger and thirst after the acute phase (Erspamer et al. 1993). No study has measured these outcomes; the basis is ethnographic and anecdotal.

Antimicrobial and immune-support effects

Dermaseptins from the secretion kill bacteria, parasites and viruses in laboratory assays (Bartels et al. 2019). No human trials exist, and whether skin-burn application yields useful blood levels is untested.

Anticancer activity

Dermaseptins B2 and B3 from the secretion inhibited prostate cancer cell growth by over 90% in laboratory dishes (van Zoggel et al. 2012). No human data exist; the basis is laboratory-only.

Benefit-Modifying Factors

• Genetic polymorphisms: No study has examined genetic modifiers of Kambô response. Variants in OPRM1 (the gene for the μ-opioid receptor) could plausibly alter dermorphin-related effects, but this is untested.
• Baseline biomarkers: No baseline biomarker predicts benefit. Survey users already rated their conviction that Kambô would help at 70.55 of 100 before first use, so expectancy rather than any measurable baseline state may shape reported benefit (Majić et al. 2021).
• Sex: The Berlin surveys included both sexes (45.5% women in Schmidt et al. 2020) but did not analyze benefits by sex; no sex-specific benefit data exist.
• Pre-existing conditions: Users most often sought help for fatigue, depression, weakened immunity, emotional trauma, addiction and anxiety (Majić et al. 2021). No study compared outcomes across conditions, so whether any condition responds better is unknown.
• Age: Surveyed users averaged 38–39 years (Majić et al. 2021; Schmidt et al. 2020); adults over 60 are essentially unstudied, so whether reported benefits hold at the older end of the adult range is unknown.
• Setting and expectancy: Most sessions were run by Western practitioners in ceremonial settings with intention-setting and preparation diets, factors the survey authors flag as possible drivers of the reported effects (Majić et al. 2021).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: there are no controlled human trials of Kambô, and harms are documented only through case reports, case reviews and uncontrolled user studies.

Medium 🟥 🟥

No risk reaches Medium: no human study of Kambô compares users with non-users, so the frequency of harms cannot be measured against a comparison group.

Low 🟥

Acute purge reaction: vomiting, racing heart, swelling and fainting

Within minutes, peptides acting on gut, vessel and heart receptors cause vomiting, rapid heartbeat, facial swelling and low blood pressure (Erspamer et al. 1993), easing within an hour. Two uncontrolled studies documented this; one, a practitioner’s review of her own 241 rituals, saw no severe events (Thompson et al. 2022).

Magnitude: Vomiting 86.53%, racing heart 67.10%, facial swelling 55.18% and loss of consciousness 12.18% among 386 users (Majić et al. 2021); facial swelling 70.5% and fainting 10.4% across 241 rituals (Thompson et al. 2022); no control group.

Severe hyponatremia (dangerously low blood sodium) and brain swelling

Water loading plus peptide-driven release of antidiuretic hormone (which makes kidneys retain water), called SIADH (syndrome of inappropriate antidiuretic hormone secretion), dilutes blood sodium. Confusion, seizures, brain swelling and one brain death followed (Leban et al. 2016; Tran et al. 2025). All evidence is case reports.

Magnitude: SIADH was diagnosed in 5 of 11 published poisoning cases (45.45%) (Sacco et al. 2022); serum sodium fell to 116–120 mmol/L after about 6 litres of water (Leban et al. 2016; Campodónico et al. 2019); no control group.

Sudden cardiac death

A 42-year-old chronic user was found dead with deltorphin A in his blood and a thickened heart muscle at autopsy (Aquila et al. 2018). A systematic review found only a few published deaths, with pre-existing risk factors as a possible amplifier (Sacco et al. 2025).

Magnitude: Not quantified in available studies. No study has measured deaths per session; fatalities are known only from individual forensic reports.

Esophageal rupture from forceful vomiting

Violent retching tore the esophagus in two published cases, from the United States and Australia, one leading to a collapsed lung and septic shock (infection-driven circulatory collapse) (Robalino Gonzaga et al. 2020; Darlington & Copertino 2023). The mechanism is intrinsic to the purge.

Magnitude: Not quantified in available studies. Only two case reports exist, and no study has counted ruptures per session.

Rhabdomyolysis (muscle breakdown) and acute kidney injury

Seizures can break down muscle, and the kidneys can be injured. One woman’s creatine kinase (CK, a muscle-damage enzyme) rose massively after seizures (Campodónico et al. 2019), and acute kidney injury with a systemic inflammatory response (body-wide inflammation) was reported from Mexico (Alvarez-Boizo et al. 2025).

Magnitude: CK peaked at 107,216 IU/L in one case (Campodónico et al. 2019), and acute kidney failure appeared in 1 of 11 published poisoning cases (Sacco et al. 2022); no control group.

Toxic liver injury

A Polish case report describes toxic hepatitis (chemical liver inflammation) after a Kambô ritual (Pogorzelska & Łapiński 2017), and raised liver enzymes recur among published poisonings (Sacco et al. 2022). Severity ranged from abnormal blood tests to treated hepatitis.

Magnitude: Not quantified in available studies. Liver injury is described only in case reports, with no study measuring its frequency.

Psychosis and lasting neuropsychiatric effects

Psychosis (loss of contact with reality) after repeated use (Roy et al. 2018), prolonged agitation (Li et al. 2018) and chronic behavioral change after seizures (Jauregui et al. 2025) are reported. Low sodium and opioid-peptide effects are proposed mechanisms (Sacco et al. 2025).

Magnitude: 1.81% (7 of 386) of surveyed users reported long-lasting mental-health deterioration, and 2 reported psychosis (Majić et al. 2021); no control group.

Immune-mediated inflammation of muscles, nerves and organs

Case reports describe dermatomyositis (immune inflammation of muscle and skin) (de la Vega et al. 2020), acute polyneuropathy (sudden nerve damage) (Mantilla-Pardo et al. 2026), a body-wide inflammatory reaction mimicking cancer progression (Peleg Hasson et al. 2021) and hypersensitivity vasculitis (allergic blood-vessel inflammation) (Medsafe). Nerve damage only partly recovered.

Magnitude: Not quantified in available studies. Each reaction is known from single case reports only.

Burns at application sites

Each session deliberately burns small dots into the skin before the secretion is applied (den Brave et al. 2014). These burns are a characteristic external sign that forensic pathologists use to recognize Kambô use (Sacco et al. 2025).

Magnitude: Not quantified in available studies. No study has followed burn healing, infection or scarring after Kambô.

Speculative 🟨

Pancreatitis

Phyllocaerulein resembles caerulein, which at high doses is the standard way to induce pancreatitis (pancreas inflammation) in animals (Dabrowski et al. 1999). No human Kambô case is documented; the basis is mechanistic.

Poisoning from look-alike secretions

Inexperienced practitioners may inadvertently use secretions from other amphibians, such as the cane toad (Rhinella marina) (Sacco et al. 2025). No confirmed poisoning from substitution is documented; the basis is isolated warnings.

Pregnancy loss

Kambô has traditionally been used to induce abortion (Sacco et al. 2025). No controlled data exist; the basis is ethnographic report only.

Risk-Modifying Factors

• Genetic polymorphisms: No study has examined genetic risk modifiers. Variants affecting sodium handling or opioid receptors (such as OPRM1) are plausible but untested.
• Baseline sodium: Low starting sodium, from diuretics (urine-increasing drugs), water fasting, endurance training or enemas, narrows the margin before dangerous hyponatremia (International Association of Kambo Practitioners (IAKP) water guidelines, a practitioner body whose members earn session fees).
• Sex: Nine of 11 published poisoning cases were women (Sacco et al. 2022), including most hyponatremia cases; how many women versus men use Kambô is unknown, so true risk by sex is unclear.
• Pre-existing conditions: Heart disease (Aquila et al. 2018), active cancer (Peleg Hasson et al. 2021), psychiatric illness (Hesselink 2018) and epilepsy (IAKP, a fee-earning practitioner body) raise the stakes.
• Age: Published cases ranged from 24 to 62 years (Sacco et al. 2022); older adults, with reduced kidney water handling and more heart disease, are theoretically at higher risk but unstudied.
• Dose and water volume: Swelling and sweating rose with the number of points (Thompson et al. 2022); hyponatremia cases followed 3.5–6 litres of water (Sacco et al. 2022).
• Practitioner and setting: Laypeople or self-administration applied Kambô in about one in ten surveyed sessions (Majić et al. 2021), removing trained monitoring.

Key Interactions & Contraindications

Prescription drugs

• Sodium-lowering drugs: SSRIs (selective serotonin reuptake inhibitors, antidepressants: sertraline, fluoxetine), thiazide diuretics (urine-increasing drugs: hydrochlorothiazide), desmopressin (synthetic antidiuretic hormone): Avoid (theoretical): each lowers sodium, compounding water retention, risking seizures. IAKP, a fee-earning practitioner body rates antidepressants low risk, skipping the morning dose.
• Blood-pressure medicines: ACE inhibitors (angiotensin-converting enzyme blockers: lisinopril), beta blockers (heart-slowing drugs: metoprolol), calcium-channel blockers (vessel relaxants: amlodipine): Caution (theoretical): additive low blood pressure and fainting. IAKP, a fee-earning practitioner body advises skipping the morning dose, resuming 8 hours after.
• Opioids (morphine, oxycodone, fentanyl, methadone, buprenorphine): Avoid (theoretical): dermorphins and deltorphins act on the same receptors, adding sedation and breathing suppression. IAKP, a fee-earning practitioner body lists fentanyl, methadone and buprenorphine as contraindicated and asks 5 days’ separation for morphine or oxycodone.
• Benzodiazepines (sedative anti-anxiety drugs: diazepam, alprazolam): Caution (theoretical): additive sedation and weaker airway protection while vomiting. IAKP, a fee-earning practitioner body rates them high risk, with 18 hours’ abstinence before and 8 hours after.
• Antiepileptic drugs (anti-seizure medications: valproate, lamotrigine) and antipsychotic drugs (medications for psychotic illness: risperidone, olanzapine): Avoid (theoretical): IAKP, a fee-earning practitioner body lists both as contraindicated; their users have epilepsy or psychotic illness, which raise seizure and psychosis risk.
• Triptans (migraine drugs that narrow blood vessels: sumatriptan, rizatriptan): Caution (theoretical): vessel narrowing may collide with Kambô’s blood-pressure and heart-rate swings. IAKP, a fee-earning practitioner body rates them high risk, with 3 days’ abstinence before.

Over-the-counter medications

• NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen): Caution (theoretical): they reduce kidney blood flow during vomiting-induced fluid loss, and acute kidney injury has followed Kambô (Alvarez-Boizo et al. 2025). Pausing them around a session is common practice.
• Sedating antihistamines (older allergy and sleep aids: diphenhydramine, doxylamine): Caution (theoretical): additive drowsiness and weaker airway protection during vomiting; avoiding same-day use mitigates this.
• Loperamide (an opioid-based antidiarrheal): Caution (theoretical): additive opioid-receptor activity with dermorphins and deltorphins, risking sedation; avoiding same-day use mitigates this.

Supplements

• Kratom (Mitragyna speciosa): Avoid (theoretical): its opioid-receptor activity adds to the secretion’s opioid peptides, risking sedation and breathing suppression; avoiding same-day use mitigates this.
• Blood-pressure-lowering supplements (beetroot nitrate, garlic extract, hawthorn): Caution (theoretical): additive fall in blood pressure and fainting; pausing them on session day is common practice.
• Diuretic herbs and licorice (dandelion leaf, licorice root): Caution (theoretical): diuretics deplete sodium, a risk IAKP, a fee-earning practitioner body flags; licorice lowers potassium, already low in several poisonings (Sacco et al. 2022). Pausing them for days beforehand mitigates this.

Other interventions

• Ayahuasca (a psychedelic brew containing DMT, dimethyltryptamine, and MAOIs, monoamine oxidase inhibitors, which slow brain-messenger breakdown): Avoid same-session use: hyponatremic seizures followed ayahuasca, then Kambô with heavy drinking (Campodónico et al. 2019). Hesselink 2018 advises against combining; the fee-earning IAKP rates it low risk.
• Bufo toad secretion (5-MeO-DMT, a potent psychedelic) and iboga or ibogaine: Avoid (theoretical): IAKP, a fee-earning practitioner body warns of extreme reactions after recent Bufo use and asks 6–8 weeks’ separation, 90 days for iboga and 10 days for ibogaine.
• Rapé (nicotine snuff) and sananga eye drops: Caution (theoretical): often given alongside Kambô (Nogueira et al. 2022); nicotine adds heart-rate and blood-pressure swings. Separating them from the session mitigates this.
• Water fasting, enemas and colonics: Avoid (theoretical): they deplete sodium. IAKP, a fee-earning practitioner body advises no Kambô after water fasting in the prior week and no enemas or colonics within 5 days before or after.

Populations who should avoid Kambô:

• Pregnancy or breastfeeding (Hesselink 2018; traditional abortifacient (abortion-inducing) use per Sacco et al. 2025)
• Severe or unstable heart disease, including structural heart disease or coronary artery disease (Hesselink 2018; Aquila et al. 2018)
• Low blood pressure syndromes, such as Shy-Drager syndrome (a degenerative disorder of blood-pressure control) (Hesselink 2018)
• Psychosis, bipolar disorder, severe depression or unstable anxiety disorders (Hesselink 2018; Roy et al. 2018)
• Epilepsy, liver cirrhosis, kidney disease, eating disorders or other conditions predisposing to low sodium (theoretical, given the hyponatremia cases; IAKP, a fee-earning practitioner body, requires careful assessment of these groups)
• Water fasting within the previous week (IAKP, a fee-earning practitioner body)
• People undergoing cancer treatment (Peleg Hasson et al. 2021)
• People with a previous immune or inflammatory reaction to Kambô (de la Vega et al. 2020)
• Children and adolescents (theoretical: a higher dose per body mass, per Sacco et al. 2025)

Risk Mitigation Strategies

Doses, volumes and timings below follow common practice unless cited.

• Cap water intake: Prevents dilutional hyponatremia. Hesselink advises about 1 litre before and no more than 1.5 litres in total (Hesselink 2018); IAKP, a fee-earning practitioner body, allows up to 3 litres per single treatment (IAKP).
• Test point first: Limits severe reactions by applying one point, then waiting; an extreme reaction is reversed by washing the secretion off (IAKP, a fee-earning practitioner body).
• Medical screening beforehand: Reduces cardiac and electrolyte catastrophes by checking sodium, kidney function, blood pressure and a resting electrocardiogram (ECG, a heart-rhythm tracing) before a first session.
• Keep dose low: Limits facial swelling and sweating, which rise with the number of points (Thompson et al. 2022); IAKP, a fee-earning practitioner body gives 3 points minimum, at most 9.
• Limit contact time: Prevents prolonged reactions and repeated drinking-and-vomiting cycles by removing the secretion after 20–40 minutes or once purging is complete (IAKP, a fee-earning practitioner body).
• Recovery position and a companion: Prevents choking on vomit and injury from fainting (Thompson et al. 2022); Hesselink recommends a trusted companion attend (Hesselink 2018).
• Emergency thresholds: Seizure or loss of consciousness calls for an ambulance; confusion, muscle spasms or drowsiness call for stopping all fluids and close monitoring, with prompt medical care if further hyponatremia signs appear (IAKP, a fee-earning practitioner body).
• Separate other substances: Avoids additive toxicity by keeping ayahuasca, Bufo, iboga and other psychoactive substances out of the same session (Hesselink 2018); IAKP, a fee-earning practitioner body, sets days-to-weeks separation for Bufo and iboga but none for ayahuasca.
• Avoid sodium-depleting practices: Prevents hyponatremia by skipping water fasts in the prior week and enemas or colonics within 5 days (IAKP, a fee-earning practitioner body).

Therapeutic Protocol

Each dose below is cited to its source; other parameters without a citation (timing, session spacing, cycling) reflect common practice.

• Western practitioner standard: A test point, then 3, 5, 7 or 9 points; secretion left 20–40 minutes; at most 3 litres of water (IAKP, a fee-earning practitioner body). Practitioner Karen Darke developed the test point.
• Doses observed in Western users: Mean 6.3 points (range 1–20) among 386 surveyed users (Majić et al. 2021); mean 4.2 points, median 3 (range 1–11), across 241 rituals (Thompson et al. 2022).
• Indigenous dosing: Kaxinawá apply 2–10 points, Yawanawá 50–60 and Katukina sometimes more than 100 at once (Nogueira et al. 2022); Francisco Gomes Muniz is credited with spreading the practice among rubber tappers and into cities.
• Conservative water approach: About 1 litre before the session and no more than 1.5 litres in total (Hesselink 2018), half the 3-litre ceiling of the fee-earning IAKP.
• Time of day: Traditionally at dawn, after fasting since the previous night (Nogueira et al. 2022).
• Placement: Traditionally the upper limbs in men and the lower limbs in women (Sacco et al. 2025).
• Half-life and duration: No human half-life data exist; the acute phase lasted under 30 minutes for about half of surveyed users and 60 minutes or more for about 15% (Majić et al. 2021).
• Single versus split dosing: Points are staged within a session (test point, then the rest); IAKP, a fee-earning practitioner body also describes same-day double or triple treatments with total water capped at 4–5 litres.
• Session spacing: Many Western practitioners offer three sessions within about one lunar month, then occasional single sessions; no study has compared schedules.
• Genetic polymorphisms: No pharmacogenetic data (on how genes alter drug response) exist; no genotype-based dose adjustment is described by any source.
• Sex: Placement differs by sex in tradition; most published poisonings involved women (Sacco et al. 2022), but no sex-specific dosing exists.
• Age: Studied users averaged 38–39 years (Majić et al. 2021; Schmidt et al. 2020); no source gives age-specific dosing. IAKP, a fee-earning practitioner body, lowers water limits for health issues; fewer points for older adults is common practice.
• Baseline biomarkers: Low baseline sodium or abnormal kidney function narrows the margin before dangerous hyponatremia, given the published cases.
• Pre-existing conditions: Heart, blood-pressure, psychiatric and pregnancy-related exclusions apply (Hesselink 2018); the fee-earning IAKP lowers water limits for people with pre-existing health issues.

Discontinuation & Cycling

• Short-term, episodic use: Kambô is used as single sessions or short series, never continuously; no lifelong regimen exists.
• Withdrawal effects: None are reported. A post-purge phase of apathy and drowsiness lasting minutes to days is common (Nogueira et al. 2022).
• Tapering: Not applicable; episodic exposure to short-acting peptides does not require tapering.
• Cycling: About three sessions within a lunar month, then occasional maintenance sessions, is common practice. No evidence shows repetition maintains benefit; chronic users appear among fatal and autoimmune cases (Aquila et al. 2018; de la Vega et al. 2020).

Sourcing and Quality

• Form and supply: Kambô is sold as dried secretion on wooden sticks through practitioners, markets and the internet (Nogueira et al. 2022); home-use kits are now sold in the United Kingdom (Lang 2026).
• Species identity: Several look-alike Phyllomedusa species share habitats, and lyophilized (freeze-dried) extracts may be misidentified or adulterated (Nogueira et al. 2022); inexperienced practitioners may inadvertently use cane toad secretions (Sacco et al. 2025).
• Potency and testing: No third-party testing, standardization or certificate of analysis exists; the same amount can be weak or extremely strong (Hesselink 2018).
• Practitioner training: Most surveyed sessions were run by Western practitioners (74.09%), fewer by indigenous healers (13.47%) (Majić et al. 2021); IAKP training is a fee-earning credential, not an independent license.
• Brands: No reputable brand or pharmacy-grade product exists; no source can be verified for purity.
• Legal and ethical sourcing: Brazil restricts access to wild animal products, and indigenous groups have raised biopiracy and benefit-sharing concerns (Nogueira et al. 2022).
• Conservation: The frog is listed as least concern, but its status may be underestimated given look-alike species not yet told apart and unregulated harvesting (Nogueira et al. 2022).

Practical Considerations

• Time to effect: The acute reaction begins within minutes. Reported lasting effects were felt for 1–6 months by 26.17% of surveyed users and over a year by 12.69% (Majić et al. 2021).
• Common pitfalls: Drinking several litres of water, combining Kambô with other psychoactive substances, self-administering, buying sticks online, and dismissing prolonged vomiting or confusion as part of the “cleanse”.
• Regulatory status, Australia: Supply and use have been banned since 1 October 2021 after the Therapeutic Goods Administration assessed Kambô as a danger to health (Victorian Department of Health).
• Regulatory status, elsewhere: Brazil’s health surveillance agency suspended therapeutic advertising in 2004 (Nogueira et al. 2022); New Zealand’s regulator states no benefit has been scientifically demonstrated (Medsafe); the United States has no explicit ban (Sacco et al. 2025).
• Cost and access: Kambô is not expensive relative to medical treatments; access is through private practitioners, retreats and online kits rather than any regulated channel.
• Interpreting reports: Online testimonials and survey results come from self-selected enthusiasts; serious harms reach the literature only when a hospital publishes them, so both benefit and harm frequencies are uncertain.

Interaction with Foundational Habits

• Sleep: Indirect. A post-purge phase of apathy and drowsiness follows (Nogueira et al. 2022); dawn sessions shorten the night before. No study has measured sleep, so scheduling sessions with a free day afterward is the main practical step.
• Nutrition: Direct. Sessions follow an overnight fast; 62.95% of surveyed users kept a preparation diet, often cutting meat, refined sugar and alcohol (Majić et al. 2021). Electrolyte-containing soups, as used traditionally, or salty food afterward counter sodium loss (IAKP, a fee-earning practitioner body).
• Exercise: Indirect, potentially harmful. Endurance athletes used to heavy drinking are a hyponatremia risk group (IAKP, a fee-earning practitioner body); low blood pressure and fluid loss would add to the strain of strenuous training on session day (theoretical). No study has examined training effects.
• Stress management: Direct. Sauvagine triggers stress-hormone release (Haddad Junior & Martins 2020), and 17.10% of users felt acute anxiety or panic (Majić et al. 2021); many pair sessions with meditation (31.35%) or intention-setting, which may shape lasting effects.

Monitoring Protocol & Defining Success

Baseline testing before a first session establishes that blood sodium, kidney function, liver enzymes, blood pressure and heart rhythm are normal, and excludes pregnancy with an hCG (human chorionic gonadotropin, the pregnancy hormone) test, because published poisonings cluster around low sodium, kidney and liver injury, heart events and pregnancy concerns. Liver injury is tracked with ALT (alanine aminotransferase, a liver enzyme) and kidney function with creatinine and eGFR (estimated glomerular filtration rate, a kidney-filtration estimate).

Ongoing monitoring is event-driven rather than calendar-driven: sodium, creatinine, ALT and CK are rechecked within 24–72 hours after any session followed by prolonged vomiting, confusion, muscle pain, dark urine or yellowing skin, and the baseline panel is repeated before each new series, or every 6–12 months for regular users.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Serum sodium	135–145 mmol/L (standard reference range)	Safety check: low sodium stops use	Main danger signal; cases reached 116–120 mmol/L (Leban et al. 2016; Campodónico et al. 2019). No fasting needed; best paired with serum osmolality (blood concentration of dissolved particles) if low
Creatinine / eGFR	Creatinine about 0.6–1.3 mg/dL (standard reference range)	Safety check: kidney injury stops use	Acute kidney injury reported (Alvarez-Boizo et al. 2025); ranges vary by laboratory, sex and muscle mass
ALT	About 7–55 U/L (standard reference range)	Safety check: liver injury stops use	Toxic hepatitis reported (Pogorzelska & Łapiński 2017); best paired with AST (aspartate aminotransferase, another liver enzyme) and bilirubin (a pigment cleared by the liver)
Creatine kinase (CK)	About 26–308 U/L, varying by sex and laboratory (standard reference range)	Safety check: muscle breakdown stops use	Peaked at 107,216 IU/L after seizures (Campodónico et al. 2019); strenuous exercise in the prior 48 hours also raises CK
Resting ECG	No established target; compare with own baseline	Safety check: hidden heart disease stops use	Fatal case had a thickened heart muscle (Aquila et al. 2018); baseline only, or after palpitations or fainting
Blood pressure	No established target; track change from own baseline	Safety check: low pressure stops use	Low blood pressure syndromes are an exclusion (Hesselink 2018); seated and standing readings
Pregnancy test (hCG)	Negative (standard reference range)	Safety check: pregnancy stops use	Traditional abortifacient use (Sacco et al. 2025); urine or blood test within days of the session

Qualitative markers define success and flag harm:

• Well-being and life satisfaction: a simple 0–10 self-rating before and at 1, 4 and 12 weeks after a series.
• Substance use: weekly count of alcoholic drinks or recreational drug uses, compared with the month before.
• Mood and anxiety: persistent low mood, panic or unusual thoughts after a session are warning signs, not part of the process.
• Energy and sleep: fatigue should resolve within a few days; lingering exhaustion or poor sleep signals a problem.
• Red flags: headache, confusion, muscle pain, dark urine, yellowing skin or vomiting beyond the session.

Emerging Research

• No ongoing trials: A ClinicalTrials.gov search in October 2026 found no ongoing interventional trial of Kambô or its peptides, so no near-term trial result will test the ritual’s claimed benefits for health-focused adults.
• Completed retreat survey: NCT05042765, an anonymous survey of 102 participants in entheogen (spiritually used psychoactive substance) retreats including Kambô users, sponsored by the commercial firm Vireo Health, completed January 2022 with no results posted. Positive results would add only uncontrolled self-report; null or harmful results would weaken the benefit case.
• Prospective safety data: Thompson et al. 2022, a retrospective review of one practitioner’s records, found no severe events across 241 rituals; prospective cohorts with sodium testing could show whether serious harm is rare enough to matter, strengthening or weakening the safety case.
• Expanding harm reports: Recent reports of acute polyneuropathy (Mantilla-Pardo et al. 2026), inflammatory kidney injury (Alvarez-Boizo et al. 2025) and chronic neuropsychiatric change (Jauregui et al. 2025) broaden the risk profile and weaken the case for use.
• Dermorphin as a pain drug: Hesselink & Schatman 2018 call for new spinal-injection trials of dermorphin. Success would support the purified peptide as a medicine, not the skin-burn ritual.
• Antimicrobial peptides: Dermaseptins are being studied against drug-resistant microbes and tumors (Bartels et al. 2019; Pucca et al. 2025). Human trials of purified peptides could confirm or refute these laboratory signals, without bearing directly on the ritual.

Conclusion

Kambô is a frog skin secretion rubbed into small skin burns, producing a brief, violent reaction of vomiting, racing heart, swelling and faintness. Users describe lasting gains in well-being and meaning and less drinking or drug use, but these accounts come only from people who chose to answer surveys, with no comparison group, and expectation and ritual setting may explain much of what they report. One of its ingredients relieved pain when purified and injected near the spine of surgical patients decades ago, which says little about the ritual itself. Laboratory signals against germs and cancer cells have never been tested in people.

The harms are documented more often than the benefits, though also only through case reports and surveys. Dangerous drops in blood sodium after heavy water drinking, seizures, brain swelling, torn food pipes, liver and kidney injury, immune attacks on muscles and nerves, lasting mental health problems and sudden deaths have all been reported, and how often they occur is unknown. Danger concentrates in people with heart disease, mental illness or pregnancy, in those already low in salt, and in sessions with large water volumes or several substances.

Most practical guidance comes from a practitioner association whose members are paid to run sessions, the only safety series reporting no serious harm came from one practitioner’s own sessions, and the one registered study was sponsored by a commercial firm. For health-focused adults, the evidence presents uncertain, self-reported gains set against severe and sometimes fatal harms of unknown frequency.

Top - Benefits - Risks - Protocol